The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Source: Eur Respir J 2002; 20: 819-825 Year: 2002
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
The TORCH (TOwards a Revolution in COPD Health) survival study protocol Source: Eur Respir J 2004; 24: 206-210 Year: 2004
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS) Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
LATE-BREAKING ABSTRACT: Safety of salmeterol/fluticasone propionate (FSC) compared to fluticasone propionate (FP) in 4-17 yr olds with asthma Source: International Congress 2016 – Paediatric asthma: from amniotic fluid to dirty streets Year: 2016
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone Source: International Congress 2017 – Asthma management Year: 2017
The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) – Interim report of post-marketing surveillance in Japan Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005